Free Trial
NASDAQ:CDT

Conduit Pharmaceuticals (CDT) Stock Price, News & Analysis

Conduit Pharmaceuticals logo
$0.56 +0.02 (+2.75%)
Closing price 04/29/2025 04:00 PM Eastern
Extended Trading
$0.56 0.00 (0.00%)
As of 08:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Conduit Pharmaceuticals Stock (NASDAQ:CDT)

Key Stats

Today's Range
$0.55
$0.58
50-Day Range
$0.54
$1.22
52-Week Range
$0.51
$350.00
Volume
701,209 shs
Average Volume
1.59 million shs
Market Capitalization
$3.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.

Conduit Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

CDT MarketRank™: 

Conduit Pharmaceuticals scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Conduit Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Conduit Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Conduit Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    222.54% of the float of Conduit Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Conduit Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Conduit Pharmaceuticals has recently increased by 98.47%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Conduit Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Conduit Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    222.54% of the float of Conduit Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Conduit Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Conduit Pharmaceuticals has recently increased by 98.47%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Conduit Pharmaceuticals has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Conduit Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    Only 5 people have searched for CDT on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Conduit Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Conduit Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    30.93% of the stock of Conduit Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 3.29% of the stock of Conduit Pharmaceuticals is held by institutions.

  • Read more about Conduit Pharmaceuticals' insider trading history.
Receive CDT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conduit Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CDT Stock News Headlines

Conduit Pharmaceuticals announces Regan appointed as CEO
You’re About to Lose Everything – Act Now or Regret It Forever
What If America's Gold Reserves Are a Lie? For decades, the U.S. government has claimed to have thousands of tons of gold locked away in Fort Knox. But there hasn't been an independent audit in over 50 years—and now, both Elon Musk and former Congressman Ron Paul are demanding answers.
Conduit Pharmaceuticals Announces Leadership Changes
Conduit expands parntership with Sarborg
See More Headlines

CDT Stock Analysis - Frequently Asked Questions

Conduit Pharmaceuticals' stock was trading at $6.86 at the start of the year. Since then, CDT stock has decreased by 91.8% and is now trading at $0.56.
View the best growth stocks for 2025 here
.

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) issued its quarterly earnings data on Friday, March, 28th. The company reported ($20.33) earnings per share (EPS) for the quarter.

Conduit Pharmaceuticals's stock reverse split on Monday, January 27th 2025. The 1-100 reverse split was announced on Thursday, January 23rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Shares of CDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Conduit Pharmaceuticals investors own include BIOLASE (BIOL), Daré Bioscience (DARE), Faraday Future Intelligent Electric (FFIE), AMC Entertainment (AMC), Cara Therapeutics (CARA), Canoo (GOEV) and Jiuzi (JZXN).

Company Calendar

Last Earnings
3/28/2025
Today
4/30/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CDT
Previous Symbol
NASDAQ:CDT
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-540,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.62) per share
Price / Book
-0.90

Miscellaneous

Free Float
710,000
Market Cap
$3.73 million
Optionable
Not Optionable
Beta
2.37
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:CDT) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners